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ulti-resistant Enterobacteriaceae
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esistance to multiple antimicrobial agents is becom-
ng more frequently seen amongst the Enterobacte-
iaceae world-wide. Much of this is result of the
ccumulation of resistances inside integrons. Thus, resis-
ance to penicillins, beta-lactamase inhibitor combina-
ion, cephalosporins, monobactams, carbapenems, ﬂuo-
oquinolones, aminoglycosides, tetracyclines and folate
ntagonists can be found in various linked combinations
ithin the family. The most problematic species is Kleb-
iella pneumoniae (KPNE), with Escherichia coli (ECOL)
nd Enterobacter species (ENTR) showing rising rates of
ulti-resistance. The increasing rates of linked resis-
ance have created signiﬁcant problems because of limited
reatment choices. Options for treatment of serious infec-
ions caused by extended-spectrum beta-lactamase-(ESBL)-
roducing KPNE and ECOL include carbapenems, considered
he drugs of choice by many, and, only if susceptible, ﬂuoro-
uinolones. Aminoglycosides have not been favoured as the
atients with multi-resistant strains are the most vulner-
ble to the toxic effects. Trimethoprim-sulfamethoxazole,
f tested as susceptible, may be used for minor infections,
ut there is little published experience with its use in seri-
us infections. Tetracyclines are generally not favoured for
nfections caused by Enterobacteriaceae. Carbapenems are
lso favoured for treatment of serious infections caused by
NTR. Again aminoglycosides have been used but have their
ttendant problems, including failure to prevent the emer-
ence of stably-derepressed mutants when used in com-
ination with third-generation cephalosporins. The recent
mergence of carbapenemases in Enterobacteriaceae in
ome parts of the world, especially KPC series enzymes in
PNE and metallo-enzymes in a number of species, have left
ew viable options for treatment. Most experience has been
ained with polymyxins, especially colistin methanosul-
onate. However, doubts about the efﬁcacy of this class
emain, related both pharmacodynamics, and to the poten-
ial for resistance selection. The only readily available alter-
ative is tigecycline, but there is limited experience with
his agent and uncertainty about the adequacy of the cur-
ent dosing regimens. The lack of novel agents active against
ram-negatives in the development pipeline heralds a bleak
uture for treating multi-resistant Enterobacteriaceae.
oi:10.1016/j.ijid.2008.05.143
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ver the last decade infections caused by multi drug-
esistant (MDR) gram-negative bacteria have become a
i
a
w
h
ol Congress on Infectious Diseases Abstracts (Invited Papers)
ontinuing and growing problem in both developing and
eveloped nations alike. Nosocomial infections caused by
ram-negative bacteria, particularly Klebsiella spp., E coli,
. aeruginosa, and Acinetobacter spp. have become increas-
ngly difﬁcult to treat due to the rising incidence of drug
esistance and the limited number of antimicrobial agents
hat are effective against them.
Acquired carbapenemases are increasingly reported in
seudomonas and Acinetobacter isolates world wide. The
mergence of these carbapenem-resistant P aeruginosa and
cinetobacter species has provided a particularly difﬁcult
hallenge for clinicians with most carbapenemase produc-
rs being broadly resistant to beta-lactams, and many are
lso resistant to ﬂuoroquinolones and aminoglycosides. Due
o the lack of therapeutic options in these patients who are
ften critically ill, clinicians are often faced with using older
nd more toxic antibiotics such as polymyxins and minocy-
line. Sulbactam which has inherent activity against A
aumannii has also been found to be useful in the treatment
f these infections. Polymyxins are now being commonly
sed to treat these multi drug resistant A baumanii and P
eruginosa with variable success. Additionally, combination
ntimicrobial therapy is frequently employed to treat infec-
ions caused by such multidrug-resistant strains adding to
he potential toxicity and cost of treatment.
Clearly the ever growing threat of the rise MDR gram
egative infections including carbapenem resistant P. aerug-
nosa and Acinetobacter spp cannot be answered by the
evelopment of new antimicrobial agents alone. A multi-
ronged strategy that includes adherence to infection
ontrol principles and antimicrobial stewardship programs
ncluding rational use of current antimicrobial agents must
emain the main stay of the response to this growing health-
are threat.
oi:10.1016/j.ijid.2008.05.144
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almonella resistant to extended-spectrum cephalosporins
e.g. ceftriaxone) has become a worldwide problem,
ith over 43 countries reporting cases. These infections
ave been associated with increased risk of bloodstream
nfections, longer duration of hospitalization and pose
treatment challenge, particularly in children. Common
echanisms of this antimicrobial resistance are mediated by
xtended-spectrum beta-lactamases and plasmid-mediated
ephalosporinases, with the CMY-2 being the most widely
isseminated enzyme. In humans, Salmonella enterica
erotypes Typhimurium, Enteriditis and Newport are the
ost common serovars associated with ceftriaxone resis-
ance. The use of antimicrobial agents in livestock,
ncluding cattle, has been associated with the emergence of
ntimicrobial-resistant nontyphoidal Salmonella strains and
ith the dissemination and transmission of these strains to
umans. In this presentation, an overview of the epidemi-
logy, risk factors, antimicrobial resistance mechanisms and
